Mywy (Drospirenone, Ethinylestradiol | Lactose Anhydrous)

The combination suppresses the hypothalamic‑pituitary‑ovarian axis, inhibiting the surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH) required for ovulation. Drospirenone also provides anti‑androgenic and antimineralocorticoid activity, while ethinylestradiol stabilises the endometrium and thickens cervical mucus, creating an environment unfavorable for fertilisation and implantation.

The specific dosing regimen for Mywy is determined by the prescribing clinician based on the product’s labeling and the patient’s individual needs. Typically, combined oral contraceptives are taken once daily for a 21‑day active phase followed by a hormone‑free interval, but the exact schedule must be confirmed by a qualified healthcare provider.

Mywy is contraindicated during pregnancy because its purpose is to prevent conception; it should be discontinued if pregnancy occurs. Limited data are available for use while breastfeeding, and clinicians usually advise against initiating combined oral contraceptives during the early postpartum period unless the benefits outweigh potential risks.

To place an order, submit an enquiry on the Mywy product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature requirements) and necessary import documentation.

Mywy contains drospirenone, which has anti‑androgenic and antimineralocorticoid properties, differentiating it from many other progestins. This profile may offer benefits such as reduced water retention and potential improvement in acne, while maintaining contraceptive efficacy comparable to other estrogen‑progestin combinations. Choice of product should consider individual risk factors and physician guidance.

Mywy tablets should be stored at or below 25 °C (77 °F) in their original blister pack, protected from moisture and direct sunlight. Keep the medication out of reach of children and avoid storing in bathrooms or other humid environments to maintain product stability throughout its shelf life.

Mywy is taken orally, usually once each day at the same time, with or without food. The typical regimen involves a series of active tablets followed by a hormone‑free interval, after which a new pack is started. Patients should follow the prescribing information and consult their healthcare provider for any missed doses.

The most serious risks include venous thromboembolism, arterial thrombosis, and severe hypertension, which can be life‑threatening. Additional concerns are liver disorders, allergic reactions such as anaphylaxis, and rare cases of severe depression or mood changes. Prompt medical attention is required if any of these events are suspected.

Mywy is contraindicated in women with a history of thromboembolic disorders, known or suspected estrogen‑dependent tumors, uncontrolled hypertension, active liver disease, or known hypersensitivity to drospirenone, ethinylestradiol or any tablet excipients. It should also be avoided during pregnancy and in individuals who are breastfeeding without medical approval.